We examined the effects of interferon (IFN)beta-1a on interleukin (IL)-12p70 and IL-10 secretion in 27 Relapsing Remitting Multiple Sclerosis (RRMS) patients, divided in responders and non-responders. In responders, IFNbeta-1a does not change the IL-12p70 concentrations, but it leads to a remarkable increase in the IL-10 production. Besides, a high IL-10/IL-12 ratio is demonstrated during the first six months of therapy. In non-responders, there were not significant alterations in the cytokine profile. We suggest that IFNbeta-1a effect in RRMS patients could be explained by its modifying effect on cytokine pattern. Moreover, we propose a possible role of IL-10/IL-12 ratio as a serum marker predictive of favorable clinical course.
Interleukin-10 and Interleukin-12 modulation in patients with relapsing-remitting Multiple Sclerosis on therapy with interferon-beta 1A: differences in responders and non responders / Carrieri, PIETRO BIAGIO; Ladogana, P.; Di Spigna, G.; de Leva, M. F.; Petracca, M.; Montella, S.; Buonavolontà, L.; Florio, C.; Postiglione, Loredana. - In: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. - ISSN 0892-3973. - STAMPA. - 30:4(2008), pp. 1-9. [10.1080/08923970802302753]
Interleukin-10 and Interleukin-12 modulation in patients with relapsing-remitting Multiple Sclerosis on therapy with interferon-beta 1A: differences in responders and non responders.
CARRIERI, PIETRO BIAGIO;POSTIGLIONE, LOREDANA
2008
Abstract
We examined the effects of interferon (IFN)beta-1a on interleukin (IL)-12p70 and IL-10 secretion in 27 Relapsing Remitting Multiple Sclerosis (RRMS) patients, divided in responders and non-responders. In responders, IFNbeta-1a does not change the IL-12p70 concentrations, but it leads to a remarkable increase in the IL-10 production. Besides, a high IL-10/IL-12 ratio is demonstrated during the first six months of therapy. In non-responders, there were not significant alterations in the cytokine profile. We suggest that IFNbeta-1a effect in RRMS patients could be explained by its modifying effect on cytokine pattern. Moreover, we propose a possible role of IL-10/IL-12 ratio as a serum marker predictive of favorable clinical course.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
